Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 11;34(1):e00115-20.
doi: 10.1128/CMR.00115-20. Print 2020 Dec 16.

New β-Lactam-β-Lactamase Inhibitor Combinations

Dafna Yahav  1   2 , Christian G Giske  3 , Alise Grāmatniece  3   4 , Henrietta Abodakpi  5 , Vincent H Tam  5 , Leonard Leibovici  2   6
Affiliations
Review

New β-Lactam-β-Lactamase Inhibitor Combinations

Dafna Yahav et al. Clin Microbiol Rev. .

Erratum in

Abstract

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam-β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa Ceftazidime-avibactam is a potential drug for treating Enterobacterales producing extended-spectrum β-lactamase (ESBL), Klebsiella pneumoniae carbapenemase (KPC), AmpC, and some class D β-lactamases (OXA-48) in addition to carbapenem-resistant Pseudomonas aeruginosa Ceftolozane-tazobactam is a treatment option mainly for carbapenem-resistant P. aeruginosa (non-carbapenemase producing), with some activity against ESBL-producing Enterobacterales Meropenem-vaborbactam has emerged as treatment option for Enterobacterales producing ESBL, KPC, or AmpC, with similar activity as meropenem against P. aeruginosa Imipenem-relebactam has documented activity against Enterobacterales producing ESBL, KPC, and AmpC, with the combination having some additional activity against P. aeruginosa relative to imipenem. None of these drugs present in vitro activity against Enterobacterales or P. aeruginosa producing metallo-β-lactamase (MBL) or against carbapenemase-producing Acinetobacter baumannii Clinical data regarding the use of these drugs to treat MDR bacteria are limited and rely mostly on nonrandomized studies. An overview on eight BLBLIs in development is also provided. These drugs provide various levels of in vitro coverage of carbapenem-resistant Enterobacterales, with several drugs presenting in vitro activity against MBLs (cefepime-zidebactam, aztreonam-avibactam, meropenem-nacubactam, and cefepime-taniborbactam). Among these drugs, some also present in vitro activity against carbapenem-resistant P. aeruginosa (cefepime-zidebactam and cefepime-taniborbactam) and A. baumannii (cefepime-zidebactam and sulbactam-durlobactam).

Keywords: ceftazidime-avibactam; ceftolozane-tazobactam; imipenem-relebactam; meropenem-vaborbactam; β-lactam–β-lactamase inhibitor combinations.

PubMed Disclaimer

References

    1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group . 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18:318–327. doi:10.1016/S1473-3099(17)30753-3. - DOI - PubMed
    1. Boucher HW, Talbot GH, Benjamin DK, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, for the Infectious Diseases Society of America . 2013. 10 × ‘20 progress—development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685–1694. doi:10.1093/cid/cit152. - DOI - PMC - PubMed
    1. Bush K, Macielag MJ. 2010. New β-lactam antibiotics and β-lactamase inhibitors. Expert Opin Ther Pat 20:1277–1293. doi:10.1517/13543776.2010.515588. - DOI - PubMed
    1. FDA. 2014. Ceftolozane-tazobactam. Center for Drug Evaluation and Research. Approval package for application number 206829Orig1s000. FDA, Silver Spring, MD.
    1. FDA. 2015. Ceftazidime-avibactam. Center for Drug Evaluation and Research. Approval package for application number 206494Orig1s000. AVYCAZ injection. FDA, Silver Spring, MD.

Publication types

MeSH terms

LinkOut - more resources